SpringerLink
Log in

Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-destiny lipoprotein

  • Letter to the Editors
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. de Groen PC (1988): Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc 63:1012–1021

    Article  CAS  PubMed  Google Scholar 

  2. de Groen PC, Wiesner RH, Krom RAF (1988): Cyclosporine Ainduced side effects related to a low total serum cholesterol level; an indication for a free cyclosporine A assay? Transplant Proc 20 (suppl 2):374–376

    CAS  PubMed  Google Scholar 

  3. Ingulli E, Tejani A, Butt KMH, Rajpoot D, Gonzalez R, Pomrantz A, Ettenger R (1990): High-dose cyclosporine therapy in recurrent nephrotic syndrome following renal transplantation. Transplantation 49:219–221

    Article  CAS  PubMed  Google Scholar 

  4. Nemunaitis J, Deeg HJ, Yee GC (1986): High cyclosporine levels after bone marrow transplantation associated with hypertriglyceridaemia. Lancet 2:744–745

    Article  CAS  PubMed  Google Scholar 

  5. Hoyer PF, Brodehl J, Ehrich JHH, Offner G (1991): Practical aspects in the use of cyclosporine in paediatric nephrology. Pediatr Nephrol 5:630–638

    Article  CAS  PubMed  Google Scholar 

  6. Faulds D, Goa KL, Benfield P (1993): Cyclosporine, a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45:953–1040

    Article  CAS  PubMed  Google Scholar 

  7. Kahan BD (1989): Cyclosporine. N Engl J Med 321(25):1725–1738

    Article  CAS  PubMed  Google Scholar 

  8. Rayyes OA, Wallmark A, Floren CH (1996): Cyclosporine inhibits catabolism of low density lipoproteins in HepG2 cells by about 25%. Hepatology 24(3):613–619

    Article  CAS  PubMed  Google Scholar 

  9. Rayyes OA, Wallmark A, Floren CH (1997): Reversal of cyclosporine inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors. Hepatology 25(4):991–994

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Kasumigaura Hospital, Department of Dermatology, Tokyo Medical University, 3-20-1 Amimachi chuo Inashikigun, 300-0332, Ibaraki, Japan

    Tomoki Okuda & Tsunao Oh-i

Authors
  1. Tomoki Okuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsunao Oh-i
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tomoki Okuda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Okuda, T., Oh-i, T. Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-destiny lipoprotein. Eur J Clin Pharmacol 58, 299–300 (2002). https://doi.org/10.1007/s00228-002-0431-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-002-0431-z

Search

Navigation